Statins, aspirin and risk of thromboembolic events in ovarian cancer patients.

[1]  G. Rennert,et al.  Statins, aspirin and risk of venous thromboembolic events in breast cancer patients , 2014, Journal of Thrombosis and Thrombolysis.

[2]  N. Gleeson,et al.  Venous thromboembolism in ovarian cancer: incidence, risk factors and impact on survival. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[3]  G. Rennert,et al.  The effect of statins on risk and survival of gynecological malignancies. , 2013, Gynecologic oncology.

[4]  T. Wakefield,et al.  Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects. , 2013, Thrombosis research.

[5]  A. Bakhru.  Effect of ovarian tumor characteristics on venous thromboembolic risk , 2013, Journal of gynecologic oncology.

[6]  A. Khorana,et al.  International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer , 2013, Journal of thrombosis and haemostasis : JTH.

[7]  S. Bojesen,et al.  Statin use and reduced cancer-related mortality. , 2012, The New England journal of medicine.

[8]  S. Berliner,et al.  Adherence to statins is associated with reduced incidence of idiopathic venous thromboembolism: real-life data from a large healthcare maintenance organisation , 2012, Heart.

[9]  J. McMurray,et al.  Effect of Statins on Venous Thromboembolic Events: A Meta-analysis of Published and Unpublished Evidence from Randomised Controlled Trials , 2012, PLoS medicine.

[10]  S. Marcella,et al.  Statin use and fatal prostate cancer , 2012, Cancer.

[11]  I. Beales,et al.  Regular statin and aspirin use in patients with Barrett’s oesophagus is associated with a reduced incidence of oesophageal adenocarcinoma , 2012, European journal of gastroenterology & hepatology.

[12]  N. Barbarroja,et al.  To cardiovascular disease and beyond: new therapeutic perspectives of statins in autoimmune diseases and cancer. , 2012, Current drug targets.

[13]  W. Ageno,et al.  Aspirin for preventing the recurrence of venous thromboembolism. , 2012, The New England journal of medicine.

[14]  P. Rothwell,et al.  Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials , 2012, The Lancet.

[15]  Gianni Tognoni,et al.  Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials , 2012, The Lancet.

[16]  M. Boccadoro,et al.  Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide. , 2012, Blood.

[17]  T. Wakefield,et al.  Statins, inflammation and deep vein thrombosis: a systematic review , 2012, Journal of Thrombosis and Thrombolysis.

[18]  D. Khemasuwan,et al.  Dose-related effect of statins in venous thrombosis risk reduction. , 2011, The American journal of medicine.

[19]  M. Monreal,et al.  Erratum to “Thirty-day mortality rate in women with cancer venous thromboembolism. Findings from the RIETE Registry” [Thrombosis Research (2011) S1-S4] , 2011 .

[20]  M. Boccadoro,et al.  Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Monreal,et al.  Thirty-day mortality rate in women with cancer and venous thromboembolism. Findings from the RIETE Registry. , 2011, Thrombosis research.

[22]  Carol Coupland,et al.  Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database , 2010, BMJ : British Medical Journal.

[23]  P. Libby,et al.  A randomized trial of rosuvastatin in the prevention of venous thromboembolism. , 2009, The New England journal of medicine.

[24]  F. Rosendaal,et al.  HMG‐CoA reductase inhibitors, other lipid‐lowering medication, antiplatelet therapy, and the risk of venous thrombosis , 2009, Journal of thrombosis and haemostasis : JTH.

[25]  C. Klersy,et al.  Stratification of Venous Thromboembolism Risk in Ovarian Cancer Patients During Chemotherapy , 2009, International Journal of Gynecologic Cancer.

[26]  Daniel R. Scoles,et al.  Impact of statin therapy on survival in epithelial ovarian cancer. , 2008, Gynecologic oncology.

[27]  J. Sehouli,et al.  Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum/paclitaxel-containing first-line chemotherapy: an exploratory analysis by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group. , 2008, Journal of Clinical Oncology.

[28]  E. Oger,et al.  Statins but not fibrates are associated with a reduced risk of venous thromboembolism: a hospital‐based case–control study , 2004, Fundamental & clinical pharmacology.

[29]  P. Libby,et al.  Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? , 2004, Circulation.

[30]  B. Psaty,et al.  HMG CoA reductase inhibitors and the risk of venous thrombosis among postmenopausal women , 2004, Journal of thrombosis and haemostasis : JTH.

[31]  M. Prins,et al.  Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. , 2002, Blood.

[32]  A. Mattioli,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[33]  R. Peto,et al.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients , 2002, BMJ : British Medical Journal.

[34]  A. Laupacis,et al.  Use of statins and the subsequent development of deep vein thrombosis. , 2001, Archives of internal medicine.

[35]  J. Danesh,et al.  Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial , 2000, The Lancet.

[36]  S. Tebbutt,et al.  Extrinsic-pathway activation in cancer with high factor Vlla and tissue factor , 1995, The Lancet.

[37]  W C Willett,et al.  Aspirin and the risk of colorectal cancer in women. , 1995, The New England journal of medicine.

[38]  J. Gold,et al.  Validation of a combined comorbidity index. , 1994, Journal of clinical epidemiology.

[39]  A. Falanga,et al.  Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. , 1985, Biochemistry.

[40]  D. Khemasuwan,et al.  Statins decrease the occurrence of venous thromboembolism in patients with cancer. , 2010, The American journal of medicine.

[41]  R. Hubbard,et al.  Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials. , 2009, British journal of clinical pharmacology.

[42]  H. Welch.  Statins and the risk of colorectal cancer. , 2005, The New England journal of medicine.

[43]  H. Jick,et al.  Statins and the risk of idiopathic venous thromboembolism. , 2002, British journal of clinical pharmacology.